National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate

NCI Responds to Hurricanes

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

YM598
An orally active synthetic substituted phenylethenesulfonamide. As a selective endothelin A receptor antagonist, YM598 inhibits endothelin-mediated mechanisms involved in tumor cell growth and progression, angiogenesis, and metastasis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)




Previous:Xolegel, Xylocaine, Xylocitin, Xyotax, Y-90 OctreoTher
Next:yoshi-864, yttrium Y 90 anti-CD19 monoclonal antibody BU12, yttrium Y 90 anti-CD45 monoclonal antibody AHN-12, yttrium Y 90 anti-CD66 monoclonal antibody BW 250/183, yttrium Y 90 daclizumab

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov